Regeneron and Roche Await Data On Potential COVID-19 Blockbuster

Early Signs Of Efficacy Expected In September

Results from COVID-19 antibody therapies from Regeneron and Lilly and several other developers are expected soon – but their window of opportunity could be short.

Antibodies
Monoclonal antibody therapies could mimic the body's own defenses against SARS-CoV-2 virus - but act faster, and help block infection

As the world waits in hope that a COVID-19 vaccine will gain approval before the end of 2020, with data readouts expected as early as October or November, data from numerous candidates for another potential line of defense against the pandemic – monoclonal antibodies (mAbs) – are also set to report in the coming months.

That is significant because even if those vaccine frontrunners can live up to expectations, they will not be a silver...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip